主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRLD
#2987
Prelude Therapeutics Incorporated
2.7
6
-5.80%
版块:
基础:
利润货币:
日范围
年范围
日变化
-5.80%
每月变动
+28.37%
6个月变化
+113.95%
年变化
+253.85%
前一天收盘价
2.9
3
Open
2.7
6
Bid
Ask
Low
2.7
6
High
2.7
6
交易量
3
市场
股票
医疗保健
PRLD
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
32.6 M
36.2 M
36.5 M
42.06 M
42.3 M
173.4 M
Valuation ratios
Enterprise value
3.11 B
561.19 M
209.92 M
198.24 M
57.85 M
124 M
Price to earnings ratio
—
—
-2.06
-2.01
-0.76
-2.7
Price to sales ratio
—
—
—
—
13.81
—
Price to cash flow ratio
—
—
-2.84
-2.29
-0.94
-3.15
Price to book ratio
—
—
1.22
1.04
0.74
1.26
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.25
0.37
0.52
0.44
0.72
0.87
Return on equity %
0.27
0.39
0.59
0.51
0.97
1.28
Return on invested capital %
10.89 K
8 576.16
4 233.67
2 161.61
1 600.72
—
Gross margin %
100
—
—
—
100
—
Operating margin %
534.21 K
—
—
—
1 995.91
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
517.54 K
—
—
—
1 816.76
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
19.41
15.37
9.42
10.79
5.3
17.36
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
0.03
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
1.77
1.77
1.36
1.32
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
7.87
7.3
1.76
4.75
Net current asset value per share
—
—
4.31
3.9
1.79
4.92
Tangible book value per share
—
—
4.13
3.93
1.73
4.86
Working capital per share
—
—
3.86
3.54
1.45
3.81
Book value per share
—
—
4.13
3.93
1.73
4.86
新闻
Prelude Therapeutics股票获Citizens重申"市场表现优于大盘"评级
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens
Prelude Therapeutics股价在FDA批准癌症药物IND申请后飙升
Prelude Therapeutics stock surges after FDA clears IND for cancer drug
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
Citizens重申Prelude Therapeutics股票评级为"市场表现优于大盘"
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens
英科达股价创52周新高,达108.81美元
Prelude Therapeutics 2025年第三季度财报电话会议记录:股价保持稳定
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness